LL-37 vs BPC-157 at a glance
| Property | LL-37 | BPC-157 |
|---|---|---|
| Structure | 37-amino-acid alpha-helical fragment of the cathelicidin precursor hCAP-18 | Synthetic pentadecapeptide (15 amino acids) derived from a gastric-juice protective protein |
| Origin | Cleaved from the CAMP gene product; first described by Agerberth et al., 1995 | Isolated and characterized by Sikiric's group, University of Zagreb, early 1990s |
| Core mechanism studied | Direct bacterial membrane disruption; angiogenesis via FPRL1; immune signaling via TLR9 | VEGFR2-Akt-eNOS angiogenic signaling; FAK/paxillin-mediated fibroblast migration |
| Antimicrobial activity | Broad spectrum in vitro, including E. coli, P. aeruginosa, and MRSA | None reported in the literature |
| Key animal data | Diabetic ob/ob mouse excisional wounds healed faster with adenoviral LL-37 delivery | Rat tendon, muscle, GI, bone, and spinal cord injury models across three decades |
| Human trial data | 34-subject randomized, placebo-controlled trial in venous leg ulcers (Gronberg et al., 2014) | Retrospective case series of 12 patients; Phase II colitis trial data unpublished |
| Approved drug status | None; limited by rapid proteolysis and a narrow safety margin | None; no completed randomized controlled trial in any indication |
An immune peptide and a gastric-juice fragment
LL-37 vs BPC-157 sets two research peptides with almost nothing in common structurally against each other on the same question: tissue repair. LL-37 is the only cathelicidin-family antimicrobial peptide the human body makes on its own, a 37-residue fragment cleaved from a larger precursor called hCAP-18. Bengt Agerberth's group at the Karolinska Institute first described that precursor in 1995 (Agerberth et al. 1995, PNAS 92:195-199), and a 2001 study by Sorensen et al. in Blood identified proteinase 3, a neutrophil granule enzyme, as the protease responsible for cleaving the inactive precursor into the mature peptide outside the cell (Sorensen et al. 2001, human neutrophil granule extracts).
BPC-157 starts from a different biological system entirely. It is a synthetic pentadecapeptide of 15 amino acids, derived from a Body Protection Compound isolated from human gastric juice. Predrag Sikiric's laboratory at the University of Zagreb Medical School characterized it in the early 1990s while investigating how the stomach lining protects itself from its own acid. Unlike LL-37, BPC-157 has no reported antimicrobial activity anywhere in the published literature; its research program runs entirely through tissue repair, angiogenesis, and gastrointestinal protection.
What LL-37's evidence shows
LL-37 kills bacteria directly. In vitro assays report minimum inhibitory concentrations in the low micromolar range against organisms including Escherichia coli, Pseudomonas aeruginosa, and methicillin-resistant Staphylococcus aureus. That antimicrobial baseline is where LL-37 departs from BPC-157 completely, but the wound-repair data is where the two compounds start to look more comparable.
A 2003 study by Koczulla et al. in the Journal of Clinical Investigation found that LL-37 induces new blood vessel growth through the formyl peptide receptor-like 1 (FPRL1) receptor on endothelial cells, increasing vessel density in a chick chorioallantoic membrane assay and improving blood flow recovery in a rabbit hind-limb ischemia model (Koczulla et al. 2003). A 2008 study by Carretero et al. delivered LL-37 by adenoviral vector to excisional wounds in diabetic ob/ob mice, a standard model for impaired healing, and found faster re-epithelialization and more granulation tissue than untreated controls, an effect traced to MAPK and PI3K-Akt pathway activation (Carretero et al. 2008, diabetic ob/ob mouse model).
LL-37 also has a completed human trial, which puts it ahead of most compounds covered on this site. Gronberg et al. ran a randomized, placebo-controlled trial of topical LL-37 in 34 patients with hard-to-heal venous leg ulcers, applying 0.5, 1.6, or 3.2 mg/mL twice weekly for four weeks after a three-week placebo run-in (Gronberg et al. 2014, n=34, Wound Repair and Regeneration). Healing rate constants were roughly six times higher than placebo at the 0.5 mg/mL dose and three times higher at 1.6 mg/mL.
The highest dose tested, 3.2 mg/mL, showed no benefit over placebo at all, a non-monotonic result the authors did not fully explain. The full mechanistic picture sits in the LL-37 research overview.
What BPC-157's evidence shows
BPC-157's best-characterized pathway also involves angiogenesis, but through a different receptor system. A 2017 study by Hsieh et al. in the Journal of Molecular Medicine found that BPC-157 increased VEGFR2 expression and internalization in human vascular endothelial cells and activated the downstream VEGFR2-Akt-eNOS signaling cascade, with treated rats in a hind-limb ischemia model showing faster blood flow recovery and higher vessel density on histology than controls (Hsieh et al. 2017).
A 2011 study by Chang et al. in the Journal of Applied Physiology found that BPC-157 accelerated outgrowth of rat Achilles tendon explants and improved fibroblast survival under oxidative stress, with phosphorylation of focal adhesion kinase and its scaffolding partner paxillin identified as the mechanism behind the migration effect (Chang et al. 2011, rat tendon fibroblast cultures). A separate 2009 study by Brcic et al. found that BPC-157 produced no measurable angiogenic response when applied directly to cell cultures, but elevated vascular marker expression in actively healing rat tendon and muscle tissue in vivo, suggesting the pro-angiogenic effect depends on the repair microenvironment rather than acting on quiescent cells (Brcic et al. 2009, rat tendon and muscle healing model).
Where BPC-157 pulls ahead of LL-37 is breadth of animal models: published studies cover tendon and ligament repair, gastric ulcer protection, bowel anastomosis healing, bone fracture repair, and spinal cord injury, almost all in rats. Where it falls behind is the strength of the human data. A 2025 systematic review by Vasireddi et al. in HSS Journal searched the literature through June 2024 and identified only one human clinical study: a retrospective case series of 12 patients with chronic knee pain who received a single intra-articular injection, of whom 7 reported sustained relief lasting over six months (Vasireddi et al. 2025, systematic review through June 2024). No control group, no randomization, and no blinding.
A separate Phase II trial of a BPC-157 enema in ulcerative colitis reportedly showed efficacy, but the full dataset has never appeared in a peer-reviewed journal. A closer look at the mechanism and the full animal-study record is in the BPC-157 research overview.
Where the two mechanisms actually diverge
LL-37's tissue-repair research is a side effect of a peptide built for host defense. Its main job is direct antimicrobial killing and immune signaling; the angiogenic and pro-migratory effects that matter for wound healing ride on receptor systems, FPRL1 and the MAPK/PI3K-Akt pathways, that evolved for a different purpose. That dual role is also where its clinical translation problem starts: rapid degradation by host and bacterial proteases, and a narrow window between antimicrobial concentrations and cytotoxicity to human cells, a problem visible in the Gronberg trial's inverted dose-response curve.
BPC-157's research program runs through tissue repair and gastrointestinal protection from the start, with no antimicrobial role to compete for the same receptor pathways. Its VEGFR2 and FAK/paxillin signaling looks mechanistically coherent within each individual study, but more than 80% of BPC-157 publications on PubMed originate from a single laboratory group, which limits how far the reported effect sizes can be generalized until independent replication catches up.
Judged strictly by trial design, LL-37 is ahead: one randomized, placebo-controlled, blinded trial beats one uncontrolled case series of 12 patients. Judged by breadth of animal evidence across tissue types and injury models, BPC-157 has the deeper published record. Neither compound is close to a wound-healing or tissue-repair drug approval, and for different reasons: LL-37 for its narrow therapeutic window, BPC-157 for its thin and largely single-source human data.
Storage, sourcing, and research handling in Indonesia
Both peptides ship as lyophilized powder and require reconstitution before use; the peptide reconstitution guide covers bacteriostatic water technique and sterile handling for either one. LL-37's strong net positive charge makes it prone to binding plasticware and glass, which can quietly reduce a working solution's concentration if the same low-protein-binding tube is not used consistently. BPC-157 is comparatively stable across a wide pH range once reconstituted, but like any peptide it degrades faster once dissolved and left at ambient temperature than it does as a sealed, desiccated powder.
Ambient temperatures of 28 to 33 degrees C and high humidity in Bali and Jakarta accelerate degradation of reconstituted solutions of either compound. Lyophilized powder stored sealed at minus 20 degrees C is stable far longer than any reconstituted vial left at room temperature; full protocol detail for tropical conditions is in the lyophilized peptide storage guide.
Concentration and draw-volume math for a specific vial can be run through the research dosing calculator. Under BPOM's framework for laboratory materials, both peptides are handled as research reagents rather than registered pharmaceuticals when supplied to Indonesian labs. Zurich Biotech supplies BPC-157 as part of its BPC-157 and TB-500 compound line, each with HPLC purity testing and a Certificate of Analysis.